Commentary on Degos Disease A C5b-9/Interferon-α-mediated endotheliopathy syndrome by Magro et al: A reconsideration of Degos Disease as hematologic or endothelial genetic disease

Dermatology Online Journal

Volumn 17, Issue 8, 2011, Pages

  Scheinfeld, Noah ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOSPORIN; ECULIZUMAB; IMMUNOGLOBULIN; PREDNISOLONE;

BENIGN TUMOR; CELL INCLUSION; CLINICAL FEATURE; COMPLEMENT SYSTEM; DISEASE ASSOCIATION; DRUG APPROVAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENETIC DISORDER; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; MALIGNANT ATROPHIC PAPULOSIS; MALIGNANT NEOPLASTIC DISEASE; NOTE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PUBLICATION; SKIN TUMOR; THROMBOSIS; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; FEMALE; MALE; METABOLISM;

COMPLEMENT MEMBRANE ATTACK COMPLEX; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MALIGNANT ATROPHIC PAPULOSIS;

EID: 80051732576     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (62)

1. Magro CM, Poe JC, Kim C, Shapiro L, Nuovo G, Crow MK, Crow YJ. Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndrome. Am J Clin Pathol 2011;135:599-610. [PubMed]
2. Degos R., J. Delort, R. Tricot (1942). Dermatite papulosqameuse atrophiante. Bull. Soc. Fr. Derm. Syph. 49, 148-150.
3. Degos R. Malignant atrophic papulosis. Br J Dermatol 1979; 100: 21-35. [PubMed]
4. Kohlmeier W. Multiple Hautnelnosen bei Thromboangiitis obliterans. Arch Dermatol Syphilol 1941; 181: 783-4.
5. Scheinfeld N. Malignant atrophic papulosis. Clin Exp Dermatol. 2007 Sep;32(5):483-7. [PubMed]
6. Scheinfeld N. Degos' disease is probably a distinct entity: a review of clinical & laboratory evidence. J Am Acad Dermatol. 2005;52(2):375-6; author reply 376-8. [PubMed]
7. Fernández-Pérez ER, Grabscheid E, Scheinfeld NS. A case of systemic malignant atrophic papulosis (Köhlmeier-Degos' disease). J Natl Med Assoc. 2005 Mar;97(3):421-5. [PubMed]
8. Scheinfeld NS, Degos Disease, eMedicine, (Accessed June 26, 2011) http://emedicine.medscape.com/article/1087180-overview
9. Ortiz A, Ceccato F, Albertengo A, Roverano S, Iribas J, Paira S. Degos cutaneous disease with features of connective tissue disease. J Clin Rheumatol. Apr 2010;16(3):132-4.
10. Mutizwa MM, Tang MB, Ng SK. Prominent Degos-like skin lesions in a patient with chronic cutaneous lupus erythematosus. Dermatol Online J. 2010 Jul 15;16(7):5. [PubMed]
11. Tsao H, Busam K, Barnhill RL, Haynes HA. Lesions resembling malignant atrophic papulosis in a patient with dermatomyositis. J Am Acad Dermatol. 1997 Feb;36(2 Pt 2):317-9. [PubMed]
12. Demitsu T, Kakurai M, Murata S, Kiyosawa T, Yaoita H. Degos' disease associated with rheumatoid arthritis. J Dermatol. 1997 Jul;24(7):488-90. [PubMed]
13. Liu CM, Harris RM, Hansen CD. Lesions resembling malignant atrophic papulosis in a patient with progressive systemic sclerosis. Cutis. 2005 Feb;75(2):101-4. [PubMed]
14. Frank H, Metz J, Müller E. Papulosis atrophicans maligna (Degos). A form of endangitis obliterans. Hautarzt. 1974 Sep;25(9):432-7. [PubMed]
15. Guhl G, Diaz-Ley B, Delgado Y, Dauden E, Fraga J, Garcia-Diez A. Wegener's granulomatosis: a new entity in the growing differential diagnosis of Degos' disease. Clin Exp Dermatol. Jul 2009;34(5):e1-3. [PubMed]
16. Grattan CE, Burton JL. Antiphospholipid syndrome and cutaneous vasoocclusive disorders. Semin Dermatol. 1991 Sep;10(3):152-9. [PubMed]
17. Pati S, Muley SA, Grill MF, Coons S, Walker R. Post-streptococcal vasculopathy with evolution to Degos' disease. J Neurol Sci. 2011 Jan 15;300(1-2):157-9. [PubMed]
18. Sibillat M, Avril MF, Charpentier P, Offret H, Bloch-Michel E. Malignant atrophic papulosis (Degos' disease): clinical review. Apropos of a case. J Fr Ophtalmol. 1986;9(4):299-304. [PubMed]
19. Harvell JD, Williford PL, White WL. Benign cutaneous Degos' disease: a case report with emphasis on histopathology as papules chronologically evolve. Am J Dermatopathol. 2001 Apr;23(2):116-23. [PubMed]
20. Zambal Z. Cutaneous deposits in alopecia mucinosa, Degos' papulosis atrophicans maligna and Buschke's scleredema. Arch Klin Exp Dermatol. 1970;237(1):105-8. German. [PubMed]
21. Yoshikawa H, Maruta T, Yokoji H, Takamori M, Yachie A, Torii Y. Degos' disease: radiological and immunological aspects. Acta Neurol Scand. 1996 Nov;94(5):353-6. [PubMed]
22. Crowson AN, Magro CM, Usmani A, McNutt NS. Immunoglobulin A-associated lymphocytic vasculopathy: a clinicopathologic study of eight patients. J Cutan Pathol. 2002 Nov;29(10):596-601. [PubMed]
23. Stejskalová A, Stanová M, Vosmík F. Malignant atrophic papulosis (Degos' syndrome). Sb Lek. 1990 Jan;92(1):1-5. [PubMed]
24. Ophthalmic changes of Degos' disease (malignant atrophic papulosis). Lee DA, Su WP, Liesegang TJ. Ophthalmology. 1984 Mar;91(3):295-9. [PubMed]
25. Egan R, Lessell S. Posterior subcapsular cataract in Degos disease. Am J Ophthalmol. Jun 2000;129(6):806-7. [PubMed]
26. Olmos L, Hunziker N, Laugier P. Microcylinders of endoplasmic reticulum in histiocytes in patients suffering from Degos' syndrome and dermatomyositis. Br J Dermatol. 1979 Feb;100(2):137-45.[PubMed]
27. Bioulac P, Doutre MS, Beylot C. Degos' malignant atrophic papulosis. Ultrastructural study of a new case. Ann Anat Pathol (Paris). 1980;25(2):111-24. [PubMed]
28. D'Avino M, Lo Schiavo A, Baroni A, Buommino E, Ruocco E. Degos' disease: a case with cutaneous lesions only: absence of paramyxovirus by PCR. Dermatology. 2000;201(3):278-9. [PubMed]
29. Dyrsen ME, Iwenofu OH, Nuovo G, Magro CM. Parvovirus B19-associated catastrophic endothelialitis with a Degos-like presentation. J Cutan Pathol. 2008 Oct;35 Suppl 1:20-5. [PubMed]
30. Levine SR, Welch KM. The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies. Arch Neurol. 1987 Aug;44(8):876-83. [PubMed]
31. Hohwy T, Jensen MG, Tøttrup A, Steiniche T, Fogh K. A fatal case of malignant atrophic papulosis (Degos' disease) in a man with factor V Leinden mutation and lupus anticoagulant. Acta Derm Venereol. 2006;86(3):245-7. [PubMed]
32. Asherson RA, Cervera R. Antiphospholipid syndrome. J Invest Dermatol. 1993 Jan;100(1):21S-27S. [PubMed]
33. Powell J, Bordea C, Wojnarowska F, Farrell AM, Morris PJ. Benign familial Degos disease worsening during immunosuppression. Br J Dermatol. 1999 Sep;141(3):524-7. [PubMed]
34. De Breucker S, Vandergheynst F, Decaux G. Inefficacy of intravenous immunoglobulins and infliximab in Degos' disease. Acta Clin Belg. 2008 Mar-Apr;63(2):99-102. [PubMed]
35. Magro C, Shapiro L, Johnson B, Salmon J, Scheinfeld N, Whelan P. Rheumatology Grand Rounds Hospital for Special Surgery (New York City) Degos Disease. Feb 10, 2010.
36. Scheinfeld N. Pairing and comparing nine diseases with Degos Disease(Malignant Atrophic Papulosis): an attempt to illustrate our understanding and direct future inquiry. Dermatol Online J. 2009;15(1):10. [PubMed]
37. Savage WJ, Brodsky RA. New insights into paroxysmal nocturnal hemoglobinuria. Hematology. 2007 Oct;12(5):371-6. [PubMed]
38. Nagarajan S, Brodsky RA, Young NS, Medof ME. Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia. Blood. 1995 Dec 15;86(12):4656-61. [PubMed]
39. Gulbis B, Eleftheriou A, Angastiniotis M, Ball S, Surrallés J, Castella M, Heimpel H, Hill A, Corrons JL. Epidemiology of rare anaemias in Europe. Adv Exp Med Biol. 2010;686:375-96. Review. [PubMed]
40. Hillmen P. The role of complement inhibition in PNH. Hematology. Am Soc Hematol Educ Program. 2008:116-23. [PubMed]
41. Yin DL, Liu LX, Zhang SG, Tian LT, Lu ZY, Jiang HC. Portal hypertension resulted from paroxysmal nocturnal hemoglobinuria: a case report and review of literature. Int J Hematol. 2009 Apr;89(3):302-4. Epub 2009 Mar 26. [PubMed]
42. Kelly R, Richards S, Hillmen P, Hill A. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab. Ther Clin Risk Manag. 2009;5:911-21. [PubMed]
43. Almeida A, Layton M, Karadimitris A. Inherited glycosylphosphatidyl inositol deficiency: a treatable CDG. Biochim Biophys Acta. 2009 Sep;1792(9):874-80. Epub 2009 Jan 9. Review. [PubMed]
44. Bessler M, Hiken J. The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program. 2008:104-10. [PubMed]
45. Weitz IC. Thrombosis in patients with paroxysmal nocturnal hemoglobinuria. Semin Thromb Hemost. 2011 Apr;37(3):315-21. [PubMed]
46. Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009 Feb 28;373(9665):759-67. [PubMed]
47. Risitano AM, Perna F, Selleri C. Achievements and Limitations of Complement Inhibition by Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: The Role of Complement Component 3. Mini Rev Med Chem. 2011 May 11. [PubMed]
48. Hill A, Rother RP, Wang X, Morris SM Jr, Quinn-Senger K, Kelly R, Richards SJ, Bessler M, Bell L, Hillmen P, Gladwin MT. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010 May;149(3):414-25. [PubMed]
49. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007 May;137(3):181-92. [PubMed]
50. Katz SK, Mudd LJ, Roenigk HH Jr. Malignant atrophic papulosis (Degos' disease) involving three generations of a family. J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):480-4. No abstract available. [PubMed]
51. Habbema L, Kisch LS, Starink TM. Familial malignant atrophic papulosis (Degos' disease)--additional evidence for heredity and a benign course. Br J Dermatol. 1986 Jan;114(1):134-5. [PubMed]
52. Kisch LS, Bruynzeel DP. Six cases of malignant atrophic papulosis (Degos' disease) occurring in one family. Br J Dermatol. 1984 Oct;111(4):469-71. [PubMed]
53. Moulin G, Barrut D, Franc MP, Pierson A. Familial Degos' atrophic papulosis (mother-daughter). Ann Dermatol Venereol. 1984;111(2):149-55. [PubMed]
54. Malignant Atrophic Papulosis http://www.ncbi.nlm.nih.gov/omim/602248
55. Vázquez-Doval FJ, Ruiz de Erenchun F, Páramo JA, Quintanilla E. Malignant atrophic papulosis. A report of two cases with altered fibrinolysis and platelet function. Clin Exp Dermatol. 1993 Sep;18(5):441-4. [PubMed]
56. Drucker CR. Malignant atrophic papulosis: response to antiplatelet therapy. Dermatologica. 1990;180(2):90-2. [PubMed]
57. Melnik B, Hariry H, Vakilzadeh F, Gropp C, Sitzer G. Malignant atrophic papulosis (Köhlmeier-Degos disease). Failure to respond to interferon alpha-2a, pentoxifylline and aspirin]. Hautarzt. 2002 Sep;53(9):618-21. [PubMed]
58. http://www.degosdisease.com/events/2007_11_09-program (Accessed December 1, 2007).
59. Schrezenmeier H, Höchsmann B. Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria. Expert Rev Hematol. 2009 Feb;2(1):7-16. [PubMed]
60. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009 Jan 29;360(5):544-6. [PubMed]
61. Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation-a case report. Transplant Proc. 2011 Jun;43(5):2097-101. [PubMed]
62. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010 May 6;362(18):1744-5. [PubMed]